Literature DB >> 20216300

Obesity among HIV-infected persons: impact of weight on CD4 cell count.

Nancy F Crum-Cianflone1, Mollie Roediger, Lynn E Eberly, Kurt Vyas, Mike L Landrum, Anuradha Ganesan, Amy C Weintrob, Robert Vincent Barthel, Brian K Agan.   

Abstract

To assess the effect of obesity on CD4 cell counts, we estimated the association of time-updated BMI categories with CD4 changes among 1001 documented HIV seroconverters. During the pre-highly active antiretroviral therapy (HAART) era, a higher BMI was associated with less reduction in CD4 cell counts over time. However during the HAART era, obese versus normal weight patients had smaller increases in CD4 cell counts (+69 versus +116 cells, P = 0.01). Lower CD4 cell counts may now be another adverse consequence of obesity.

Entities:  

Mesh:

Year:  2010        PMID: 20216300      PMCID: PMC2878190          DOI: 10.1097/QAD.0b013e328337fe01

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  20 in total

1.  Body mass index, diabetes, and C-reactive protein among U.S. adults.

Authors:  E S Ford
Journal:  Diabetes Care       Date:  1999-12       Impact factor: 19.112

2.  Wasting and obesity in HIV outpatients.

Authors:  L M Hodgson; H Ghattas; H Pritchitt; A Schwenk; L Payne; D C Macallan
Journal:  AIDS       Date:  2001-11-23       Impact factor: 4.177

3.  When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort.

Authors:  G Shor-Posner; A Campa; G Zhang; N Persaud; M J Miguez-Burbano; J Quesada; M A Fletcher; J B Page; M K Baum
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

4.  Obesity and lymphocyte subsets in virologically suppressed HIV-infected patients.

Authors:  Oluwatoyin M Adeyemi; Sonia Vibhakar; Arthur T Evans
Journal:  Metabolism       Date:  2009-06-18       Impact factor: 8.694

5.  AIDS wasting syndrome: trends, influence on opportunistic infections, and survival.

Authors:  Mark S Dworkin; John M Williamson
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

6.  Complications of obesity.

Authors:  G A Bray
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

7.  T lymphopaenia in relation to body mass index and TNF-alpha in human obesity: adequate weight reduction can be corrective.

Authors:  S Tanaka; F Isoda; Y Ishihara; M Kimura; T Yamakawa
Journal:  Clin Endocrinol (Oxf)       Date:  2001-03       Impact factor: 3.478

8.  Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort.

Authors:  Clara Y Jones; Joseph W Hogan; Brad Snyder; Robert S Klein; Anne Rompalo; Paula Schuman; Charles C Carpenter
Journal:  Clin Infect Dis       Date:  2003       Impact factor: 9.079

9.  Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.

Authors:  Peter W F Wilson; Ralph B D'Agostino; Lisa Sullivan; Helen Parise; William B Kannel
Journal:  Arch Intern Med       Date:  2002-09-09

10.  Leptin inhibits the anti-CD3-driven proliferation of peripheral blood T cells but enhances the production of proinflammatory cytokines.

Authors:  Graham M Lord; Giuseppe Matarese; Jane K Howard; Stephen R Bloom; Robert I Lechler
Journal:  J Leukoc Biol       Date:  2002-08       Impact factor: 4.962

View more
  31 in total

Review 1.  Immunomodulation at epithelial sites by obesity and metabolic disease.

Authors:  Kitty P Cheung; Kristen R Taylor; Julie M Jameson
Journal:  Immunol Res       Date:  2012-06       Impact factor: 2.829

2.  High risk of obesity and weight gain for HIV-infected uninsured minorities.

Authors:  Barbara S Taylor; Yuanyuan Liang; L Sergio Garduño; Elizabeth A Walter; Margit B Gerardi; Gregory M Anstead; Delia Bullock; Barbara J Turner
Journal:  J Acquir Immune Defic Syndr       Date:  2014-02-01       Impact factor: 3.731

3.  An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.

Authors:  John R Koethe; Cathy A Jenkins; Bryan E Shepherd; Samuel E Stinnette; Timothy R Sterling
Journal:  Clin Infect Dis       Date:  2011-09-26       Impact factor: 9.079

4.  Comparative Outcomes of Bariatric Surgery in Patients With and Without Human Immunodeficiency Virus.

Authors:  Gautam Sharma; Andrew T Strong; Mena Boules; Chao Tu; Samuel Szomstein; Raul Rosenthal; John Rodriguez; Alan J Taege; Matthew Kroh
Journal:  Obes Surg       Date:  2018-04       Impact factor: 4.129

5.  Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy.

Authors:  Brandon Palermo; Ronald J Bosch; Kara Bennett; Jeffrey M Jacobson
Journal:  HIV Clin Trials       Date:  2011 Jul-Aug

6.  Body mass index and early CD4 T-cell recovery among adults initiating antiretroviral therapy in North America, 1998-2010.

Authors:  J R Koethe; C A Jenkins; B Lau; B E Shepherd; M J Silverberg; T T Brown; A J Blashill; A Anema; A Willig; S Stinnette; S Napravnik; J Gill; H M Crane; T R Sterling
Journal:  HIV Med       Date:  2015-05-11       Impact factor: 3.180

7.  Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals.

Authors:  Melissa Herrin; Janet P Tate; Kathleen M Akgün; Adeel A Butt; Kristina Crothers; Matthew S Freiberg; Cynthia L Gibert; David A Leaf; David Rimland; Maria C Rodriguez-Barradas; Chris B Ruser; Kevan C Herold; Amy C Justice
Journal:  J Acquir Immune Defic Syndr       Date:  2016-10-01       Impact factor: 3.731

8.  Weight change after antiretroviral therapy and mortality.

Authors:  Bianca Yuh; Janet Tate; Adeel A Butt; Kristina Crothers; Matthew Freiberg; David Leaf; Mary Logeais; David Rimland; Maria C Rodriguez-Barradas; Christopher Ruser; Amy C Justice
Journal:  Clin Infect Dis       Date:  2015-03-11       Impact factor: 9.079

9.  Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.

Authors:  Graeme J Moyle; Hélène Hardy; Awny Farajallah; Michelle DeGrosky; Donnie McGrath
Journal:  Clin Drug Investig       Date:  2014-04       Impact factor: 2.859

10.  A pandemic of the poor: social disadvantage and the U.S. HIV epidemic.

Authors:  Jennifer A Pellowski; Seth C Kalichman; Karen A Matthews; Nancy Adler
Journal:  Am Psychol       Date:  2013 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.